UBE2T and non-small cell lung adenocarcinoma: Of note we did not identify a significant proportion of molecular alterations in those tumors except for non-small cell lung adenocarcinoma patients, where UBE2T was amplified in 7.4% of the tumors, and DTL in 6.5% (Table 3).